- Home
- PHAR vs PCN Comparison
PHAR vs PCN Comparison
Compare PHAR & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PCN
- Stock Information
- Founded
- PHAR 1988
- PCN 2001
- Country
- PHAR Netherlands
- PCN United States
- Employees
- PHAR N/A
- PCN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- PHAR Health Care
- PCN Finance
- Exchange
- PHAR Nasdaq
- PCN Nasdaq
- Market Cap
- PHAR 707.9M
- PCN 802.3M
- IPO Year
- PHAR N/A
- PCN N/A
- Fundamental
- Price
- PHAR $10.96
- PCN $12.65
- Analyst Decision
- PHAR Strong Buy
- PCN
- Analyst Count
- PHAR 3
- PCN 0
- Target Price
- PHAR $30.00
- PCN N/A
- AVG Volume (30 Days)
- PHAR 5.3K
- PCN 218.7K
- Earning Date
- PHAR 07-31-2025
- PCN 01-01-0001
- Dividend Yield
- PHAR N/A
- PCN 9.73%
- EPS Growth
- PHAR N/A
- PCN N/A
- EPS
- PHAR N/A
- PCN N/A
- Revenue
- PHAR $339,836,000.00
- PCN N/A
- Revenue This Year
- PHAR $12.88
- PCN N/A
- Revenue Next Year
- PHAR $8.54
- PCN N/A
- P/E Ratio
- PHAR N/A
- PCN N/A
- Revenue Growth
- PHAR 22.44
- PCN N/A
- 52 Week Low
- PHAR $6.73
- PCN $10.70
- 52 Week High
- PHAR $12.61
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- PHAR 58.06
- PCN 53.87
- Support Level
- PHAR $9.54
- PCN $12.58
- Resistance Level
- PHAR $10.46
- PCN $12.60
- Average True Range (ATR)
- PHAR 0.37
- PCN 0.06
- MACD
- PHAR 0.10
- PCN 0.01
- Stochastic Oscillator
- PHAR 81.20
- PCN 93.14
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.